Nasdaq · CIK 0000034956
TENX TENAX THERAPEUTICS, INC.
Insider trading from SEC Form 4. Last filing 25 d ago. Close $1.87 on Oct 9, 2026, +36% from the 52-week low and -90% from the high.
Last 90 days
Net insider value
+$3.1M
more bought than sold
Buys
5
$3.1M by 4 insiders
Sells
0
$0 by 0 insiders
Insiders on file
9
with a Form 4 at this company
Price and insider trades, last year
TENXOct 9, 2026 · close 1.87
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at TENAX THERAPEUTICS, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | Declan Doogan director buy | $102k 53,000 shares | +2331% | - | |
| 50Moderate | Christopher Thomas Giordano CEO buy | $20k 10,850 shares | +96% | - | |
| 47Moderate | Thomas R Staab II Chief Financial Officer buy | $11k 5,675 shares | +57% | - | |
| 55Moderate | ADAR1 Capital Management, LLC owner buy | $1.6M 900,000 shares | +16% | - | |
| 50Moderate | ADAR1 Capital Management, LLC owner buy | $1.4M 770,333 shares | +16% | - |
Transactions
The last 18 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 16, 2026 | Declan Doogan director | POpen-market purchase Common Stock | +53,000 | $1.92 | $102k | 55,274 | 25 d ago |
| Sep 11, 2026 | Christopher Thomas Giordano CEO | POpen-market purchase Common Stock | +6,000 | $1.88 | $11k | 17,324 | 27 d ago |
| Sep 11, 2026 | Thomas R Staab II Chief Financial Officer | POpen-market purchase Common Stock | +5,675 | $1.94 | $11k | 15,675 | 27 d ago |
| Sep 15, 2026 | Christopher Thomas Giordano CEO | POpen-market purchase Common Stock | +4,850 | $1.82 | $8,837 | 22,174 | 27 d ago |
| Sep 3, 2026 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Stockindirect: See Footnote | +900,000 | $1.78 | $1.6M | 6,524,151 | 34 d ago |
| Aug 31, 2026 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Stockindirect: See Footnote | +403,571 | $1.79 | $723k | 5,257,389 | 40 d ago |
| Sep 1, 2026 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Stockindirect: See Footnote | +179,058 | $1.80 | $322k | 5,436,447 | 40 d ago |
| Sep 2, 2026 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Stockindirect: See Footnote | +187,704 | $1.80 | $338k | 5,624,151 | 40 d ago |
| Jul 1, 2025 | June Sherie Almenoff director | AGrant or award Stock Option (right to buy)derivative | +80,000 | $0.00 | $0 | 80,000 | Jul 3, 2025 |
| May 16, 2025 | Christopher Thomas Giordano CEO | AGrant or award Stock Option (right to buy)derivative | +1,400,000 | $0.00 | $0 | 1,400,000 | May 20, 2025 |
| May 16, 2025 | Stuart Rich Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +625,000 | $0.00 | $0 | 625,000 | May 20, 2025 |
| Dec 10, 2024 | June Sherie Almenoff director | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Dec 12, 2024 |
| Dec 10, 2024 | Christopher Thomas Giordano CEO | AGrant or award Stock Option (right to buy)derivative | +1,250,000 | $0.00 | $0 | 1,250,000 | Dec 12, 2024 |
| Dec 10, 2024 | Robyn Hunter director | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Dec 12, 2024 |
| Dec 10, 2024 | Michael H. Davidson director | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Dec 12, 2024 |
| Dec 10, 2024 | Declan Doogan director | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Dec 12, 2024 |
| Dec 10, 2024 | Gerald T Proehl director | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Dec 12, 2024 |
| Dec 10, 2024 | Stuart Rich Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +500,000 | $0.00 | $0 | 500,000 | Dec 12, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- ADAR1 Capital Management, LLCowner
- June Sherie Almenoffdirector
- Michael H. Davidsonceo, officer, director
- Declan Doogandirector
- Christopher Thomas GiordanoCEO
- Robyn Hunterdirector
- Gerald T Proehldirector, ceo, president, chair, officer, owner
- Stuart RichChief Medical Officer
- Thomas R Staab IIChief Financial Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.